Bacillary angiomatosis in an immunosuppressed dog.
A dog being treated with immunosuppressive doses of prednisone and azathioprine for pancytopenia of unknown origin, developed, over a 2-week period, multiple erythematous nodular lesions in the skin including footpads. Skin samples revealed lesions identical to those of human bacillary angiomatosis (BA). The nodules were composed of multifocal proliferations of capillaries, each lined by protuberant endothelial cells. The capillary clusters were separated by an oedematous connective tissue, lightly infiltrated with degenerate inflammatory cells, including neutrophils and macrophages. Tissue sections stained with Warthin-Starry silver stain revealed large numbers of positively stained bacilli in the stromal tissue, most heavily concentrated around the proliferating capillaries. Lesions of vascular degeneration and inflammation were evident. Bartonella vinsonii subsp. berkhoffii genotype 1 was independently amplified and sequenced from the blood and the skin tissue. The pathognomonic nature of the histological lesions, demonstration of compatible silver-stained bacilli in the tissue, and identification of B. vinsonii subsp. berkhoffii in the blood and tissue indicates that this is most likely the aetiologic agent responsible for the lesions. Antibiotic therapy was successful in resolving the nodules. It would appear that B. vinsonii subsp berkhoffii, like Bartonella henselae and Bartonella quintana, has the rare ability to induce angioproliferative lesions, most likely in association with immunosuppression. The demonstration of lesions identical to those of human BA in this dog is further evidence that the full range of clinical manifestations of human Bartonella infection occurs also in canines.
Yager
Julie A
JA
Yager-Best Veterinary Surgical Pathology, Guelph, ON, Canada. jyager@uoguelph.ca
Best
Susan J
SJ
Maggi
Ricardo G
RG
Varanat
Mrudula
M
Znajda
Nadine
N
Breitschwerdt
Edward B
EB
D016917:Angiomatosis, Bacillary / Q000188:drug therapy / Q000276:immunology / Q000662:veterinary*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D017963:Azithromycin / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use; D004285:Dogs; D005260:Female; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D010198:Pancytopenia / Q000188:drug therapy / Q000662:veterinary; D011241:Prednisone / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D007166:Immunosuppressive Agents; D002981:Clindamycin; D017963:Azithromycin; D001379:Azathioprine; D011241:Prednisone